AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Infect Dis
Hlavní autoři: Ivashchenko, Andrey A, Dmitriev, Kirill A, Vostokova, Natalia V, Azarova, Valeria N, Blinow, Andrew A, Egorova, Alina N, Gordeev, Ivan G, Ilin, Alexey P, Karapetian, Ruben N, Kravchenko, Dmitry V, Lomakin, Nikita V, Merkulova, Elena A, Papazova, Natalia A, Pavlikova, Elena P, Savchuk, Nikolay P, Simakina, Elena N, Sitdekov, Tagir A, Smolyarchuk, Elena A, Tikhomolova, Elena G, Yakubova, Elena V, Ivachtchenko, Alexandre V
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Brief Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7454388/
https://ncbi.nlm.nih.gov/pubmed/32770240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciaa1176
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky